Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Drive Radical Advances in Human Health
Business Model:
Revenue: $0
Employees: 0-0
Address: 665 3rd St
City: San Francisco
State: CA
Zip: 94107
Country: US
Alix Ventures: Driving Patient Impact - Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of TechBio, a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality &a; effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is composed of serial VC backed Life Sciences founders with experience in raising capital, scaling teams, running labs, navigating regulatory mazes, partnering with pharma &a; the many fires that consist of operating an early stage company. We’ve been in your shoes before, we pride ourselves in being the VC we wish we had on our own cap tables, founders we are here to help! SAB/MAB: Composed of top VC-backed PhD Life Sciences founders, our scientific &a; medical advisory board aids our investment team in both technical &a; clinical diligence - thus providing a multitude of expertise &a; fluency across a wide variety of Life Science sub-domains. Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, &a; team building, amongst others. In addition, dedicated to supporting our portfolio is our operating partner - Mark Pulido (5x HC/LS CEO - previously of Novartis, McKesson, &a; Ability) &a; our extensive network of industry executives spanning Top 25 Pharma, major health systems, &a; large payors. Limited Partners: Anchored by leading strategic LPs making up some of the best venture capital firms in the world, veteran founders, &a; industry experts. Alix is here to fill the void for early stage Life Sciences specific capital in Silicon Valley.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2019 | Pair Team | Seed Round | 2.7M |
12/2021 | Zafrens | Venture Round | 0 |
5/2020 | Xilis | Seed Round | - |
12/2021 | Zafrens | Seed Round | 6M |
1/2022 | 64x Bio | Series A | 0 |
10/2021 | Teiko.bio | Series A | 11.6M |
9/2019 | Pair Team | Pre Seed Round | 0 |
7/2021 | Xilis | Series A | 0 |
7/2022 | Xilis | Series A | 0 |
6/2022 | Endpoint Health | Series A | 0 |
12/2021 | Pair Team | Venture Round | 7.3M |
3/2020 | Circularis Biotechnologies | Seed Round | - |
11/2021 | Zafrens | Pre Seed Round | - |
7/2020 | Elegen | Seed Round | - |
7/2022 | Xilis | Series A | 0 |
6/2022 | Endpoint Health | Series A | 0 |
1/2022 | 64x Bio | Series A | 0 |
12/2021 | Zafrens | Venture Round | 0 |
12/2021 | Pair Team | Seed Round | 0 |
11/2021 | Zafrens | Pre Seed Round | - |
10/2021 | Teiko.bio | Series A | 0 |
7/2021 | Xilis | Series A | 0 |
7/2020 | Elegen | Seed Round | - |
5/2020 | Xilis | Seed Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|